Malaria, babesiosis, trypanosomosis, and leishmaniasis are some of the most life-threatening parasites, but the range of drugs to treat them is limited. An effective, safe, and low-cost drug with a large activity spectrum is urgently needed. For this purpose, an aryl amino alcohol derivative called Alsinol was resynthesized, screened in silico, and tested against Plasmodium, Babesia, Trypanosoma, and Leishmania. In silico Alsinol follows the Lipinski and Ghose rules.
Endoperoxides (EPs) appear to be promising drug candidates against protozoal diseases, including malaria and leishmaniasis. Previous studies have shown that these drugs need an intracellular activation to exert their pharmacological potential. The efficiency of these drugs is linked to the extensive iron demand of these intracellular protozoal parasites.
Many plants have antiplasmodial properties but nobody really knows why some do and others do not. We have paid most of our attention to artemisinin and derivatives, to flavonoids and antioxidants, swamped and blinded by thousands of papers on these molecules, billions invested and earned in ACTs, the prohibition of clinical trials with Artemisia annua by WHO-Geneva, the Vatican of malaria, and the colonial ITG-Antwerp. And we have forgotten that there are other molecules in Artemisia which may play an equivalent or stronger role.
THE BREAKING NEWS PAPER OF MAVONDO
Objectors to applications in public health assert that because it is impossible to obtain informed consent that the technology is inadequate. What a remarkable conclusion!
In the early 1990s, when scientists first came up with a radical new idea to engineer mosquitoes that would no longer be capable of transmitting pathogens, some thought of an even more fantastic application. Use mosquitoes to vaccinate people. Silence followed until now...